Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Georgianos PI, Agarwal R.

Kidney Int. 2018 Feb;93(2):325-334. doi: 10.1016/j.kint.2017.08.038. Epub 2017 Dec 21.

PMID:
29276100
2.

How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders.

Lainscak M.

Card Fail Rev. 2017 Apr;3(1):33-39. doi: 10.15420/cfr.2017.2.1.

3.

Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.

Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.

J Am Heart Assoc. 2017 Jul 19;6(7). pii: e005428. doi: 10.1161/JAHA.116.005428.

4.

Quality of Care for Patients With Chronic Kidney Disease in the Primary Care Setting: A Retrospective Cohort Study From Ontario, Canada.

Nash DM, Brimble S, Markle-Reid M, McArthur E, Tu K, Nesrallah GE, Grill A, Garg AX.

Can J Kidney Health Dis. 2017 May 23;4:2054358117703059. doi: 10.1177/2054358117703059. eCollection 2017.

5.

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.

Lesko LJ, Offman E, Brew CT, Garza D, Benton W, Mayo MR, Romero A, Du Mond C, Weir MR.

J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):434-446. doi: 10.1177/1074248417691135. Epub 2017 Feb 13.

6.

Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.

Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, Navaneethan SD.

Am J Nephrol. 2015;41(6):456-63. doi: 10.1159/000437151. Epub 2015 Jul 25.

7.

Potassium abnormalities in current clinical practice: frequency, causes, severity and management.

Eliacik E, Yildirim T, Sahin U, Kizilarslanoglu C, Tapan U, Aybal-Kutlugun A, Hascelik G, Arici M.

Med Princ Pract. 2015;24(3):271-5. doi: 10.1159/000376580. Epub 2015 Mar 11.

8.

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study.

Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

BMJ. 2014 Oct 30;349:g6196. doi: 10.1136/bmj.g6196.

9.

Runner's new diet, his collapse, and his ECG: when a rapid ECG diagnosis can save the day.

Ringer M, Pulfrey S.

Can Fam Physician. 2014 Apr;60(4):340-4. No abstract available.

10.

Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.

Espinel E, Joven J, Gil I, Suñé P, Renedo B, Fort J, Serón D.

BMC Res Notes. 2013 Aug 1;6:306. doi: 10.1186/1756-0500-6-306.

11.

Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission.

Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX.

BMJ Open. 2012 Dec 28;2(6). pii: e002011. doi: 10.1136/bmjopen-2012-002011. Print 2012.

12.

Severe hyperkalemia requiring hospitalization: predictors of mortality.

An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, Lim CS.

Crit Care. 2012 Nov 21;16(6):R225. doi: 10.1186/cc11872.

13.

Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1234-41. doi: 10.2215/CJN.01150112. Epub 2012 May 17.

14.

Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation.

Norman SP, Kommareddi M, Ojo AO, Luan FL.

Transplantation. 2011 Oct 15;92(7):796-801. doi: 10.1097/TP.0b013e31822dc36b.

15.

Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.

White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL.

J Clin Hypertens (Greenwich). 2010 Oct;12(10):765-75. doi: 10.1111/j.1751-7176.2010.00352.x.

16.

Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.

Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, Garg AX.

Clin J Am Soc Nephrol. 2010 Sep;5(9):1544-51. doi: 10.2215/CJN.01970310. Epub 2010 Jul 1.

17.

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.

Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R.

Clin J Am Soc Nephrol. 2010 May;5(5):762-9. doi: 10.2215/CJN.05850809. Epub 2010 Mar 4.

18.

Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.

Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, Saylor G, Smith DH.

J Gen Intern Med. 2010 Apr;25(4):326-33. doi: 10.1007/s11606-009-1228-x. Epub 2010 Jan 20.

19.

Keishibukuryogan reduces renal injury in the early stage of renal failure in the remnant kidney model.

Nakagawa T, Tashiro I, Fujimoto M, Jo M, Sakai S, Oka H, Goto H, Shimada Y, Shibahara N.

Evid Based Complement Alternat Med. 2011;2011:914249. doi: 10.1093/ecam/nep089. Epub 2011 May 3.

20.

The frequency of hyperkalemia and its significance in chronic kidney disease.

Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC.

Arch Intern Med. 2009 Jun 22;169(12):1156-62. doi: 10.1001/archinternmed.2009.132.

Supplemental Content

Support Center